PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report) traded up 0% during trading on Friday . The stock traded as high as $0.6108 and last traded at $0.5901. 30,044 shares changed hands during trading, an increase of 240% from the average session volume of 8,831 shares. The stock had previously closed at $0.59.
PharmaCyte Biotech Price Performance
The firm’s fifty day moving average price is $0.70 and its 200 day moving average price is $0.73.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical?stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose?based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.
In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide.
See Also
- Five stocks we like better than PharmaCyte Biotech
- 3 Stocks Whose Charts May Be Signaling the Next Big Move
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
